The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.

Zebra Technologies Corporation is a buy for 2025, with growth in retail and healthcare and an $8B market expansion. Click ...

The Tron saga continues to push boundaries between stunning visuals and profound questions about artificial intelligence, ...

The styling divides opinion with its 1980s angular aesthetic, but that's precisely why values have stayed suppressed, with ...

Joe Rogan was left stunned after Harvard astrophysicist Avi Loeb revealed discussions about alien tech tied to 3I/ATLAS are ...

A newly discovered protein from Earth's toughest animal is inspiring breakthrough therapies for cancer and cardiovascular ...

The Supreme Court has agreed to take up two major gun cases this term, and could take up more Second Amendment cases this ...

The entorhinal/hippocampal circuit is known from past studies to be crucial for both memory formation and the recalling of ...

After FOMC rate cuts and a stalled market, traders are turning to meme coins and presales for high-risk rewards. However, one ...

Shipping and mailing solutions provider Pitney Bowes (NYSE:PBI) missed Wall Street’s revenue expectations in Q3 CY2025, with ...

Home appliances manufacturer Whirlpool (NYSE:WHR) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with ...

Astrocytes have traditionally been thought to have a supporting role in the brain, but new research shows they also play a ...